Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 49

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 49
---

of 3,036,283 shares of our common stock are sold at a price of $65.87 per share pursuant to this prospectus supplement, which was the last reported sale price of our common stock on the Nasdaq Global Market on August 11, 2025, for aggregate
gross proceeds of approximately $200.0 million, after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $61.90 per share, representing the difference between our as
adjusted net tangible book value per share as of June 30, 2025 after giving effect to this offering at the assumed offering price. The exercise of outstanding stock options may result in further dilution of your investment. See the section
titled “Dilution” below for a more detailed illustration of the dilution you would incur if you participate in this offering.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or
paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable
future. Any return to stockholders will therefore be limited to the appreciation of their stock.

You may experience future dilution as a result of future equity offerings.

In order to raise additional capital, we may in the future offer additional shares of our common stock or
other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share paid by any investor in this offering. We may sell shares or other securities in any other offering at a price per share
that is less than the price per share paid by any investor in this offering, and investors

S-6

purchasing shares or other securities in the future could have rights superior to you. The price per share at which we sell additional shares of our common stock, or securities convertible or
exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by any investor in this offering.

It is not possible to predict the aggregate proceeds resulting from sales made under the sales agreement.

Subject to certain limitations
in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Leerink Partners and Cantor at any time throughout the term of the sales agreement. The number of shares that are sold through Leerink